Cathie Wood’s ARK ETF adjusts portfolio with Tesla and CRISPR stock trades

Published 21/03/2025, 01:08
© Reuters

Cathie Wood’s ARK ETFs have released their daily trades for Thursday, March 20th, 2025, showcasing a series of strategic buys and sells across the biotech, communications, and technology sectors. The largest transaction of the day was the purchase of 100,706 shares of CRISPR Therapeutics AG (NASDAQ:CRSP), split between ARKK and ARKG ETFs, with a total value of approximately $4.22 million. This move underscores ARK’s continuing confidence in the gene-editing company, adding to its position from previous days.

Another notable trade was the acquisition of 103,028 shares of Iridium Communications Inc (NASDAQ:IRDM), valued at around $2.84 million, distributed across three ARK ETFs: ARKK, ARKQ, and ARKX (NYSE:ARKX). This follows a consistent pattern of investment in Iridium, as ARK has been accumulating shares in the satellite communications firm throughout the week.

ARK also increased its stake in Tesla Inc (NASDAQ:TSLA), with a purchase of 9,351 shares through its ARKK ETF, totaling approximately $2.21 million. This buy reflects a sustained interest in the electric vehicle giant, despite the stock’s volatility.

In the realm of biotechnology, ARK’s ETFs made several key purchases, including 298,652 shares of Absci Corp (NASDAQ:ABSI) for roughly $890,000 through ARKG and 104,341 shares of Intellia Therapeutics Inc (NASDAQ:NTLA) for about $970,000, split between ARKK and ARKG. Additionally, the funds bought 190,153 shares of Pacific Biosciences of California Inc (NASDAQ:PACB) and 161,298 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), with values of $237,691 and $1.06 million, respectively.

On the selling side, ARK offloaded 4648 shares of Meta Platforms Inc (NASDAQ:META) from its ARKK ETF, amounting to approximately $2.71 million. This sale is part of a broader trend of reducing exposure to the social media conglomerate, following a significant sell-off the previous week. Other sales included smaller positions in Amgen Inc (NASDAQ:AMGN), UiPath Inc (NYSE:PATH), Repare Therapeutics Inc (NASDAQ:RPTX), and Veeva Systems Inc (NYSE:VEEV), with dollar values ranging from $5,305 to $190,081.

Investors following ARK’s movements will note the ETF’s ongoing strategy of focusing on innovative companies with disruptive potential, while tactically adjusting holdings in response to market conditions and company performance. These daily trade reports offer a glimpse into Cathie Wood’s investment philosophy and the dynamic nature of ARK’s portfolio management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.